GlassScriptPhysician profile
Anouk Lily Thomas
NPI 1114899739
$871.14
in general payments reported to CMS, 2019-2025
19 companies · $871 in 2025
The $871 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $806 · Education: $65.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $806.14 |
| Education | $65.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $98.71 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $95.68 | 2025 | Lynparza, Imfinzi, Tagrisso |
| Merck Sharp & Dohme LLC | $89.80 | 2025 | Keytruda Qlex, Keytruda |
| Incyte Corporation | $87.07 | 2025 | Monjuvi |
| Janssen Biotech, INC. | $58.69 | 2025 | Tecvayli, Rybrevant |
| Pfizer INC. | $58.14 | 2025 | |
| Karyopharm Therapeutics INC. | $57.64 | 2025 | Xpovio |
| Genentech USA, INC. | $34.92 | 2025 | Tecentriq |
| Geron Corporation | $34.37 | 2025 | Rytelo |
| Takeda Pharmaceuticals U.S.A., INC. | $33.62 | 2025 | Fruzaqla |
| Deciphera Pharmaceuticals INC. | $33.46 | 2025 | Qinlock, Romvimza |
| E.R. Squibb & Sons, L.L.C. | $33.40 | 2025 | Opdivo |
| Celgene Corporation | $30.22 | 2025 | Reblozyl |
| Taiho Oncology, INC. | $26.60 | 2025 | |
| Sobi, INC | $26.49 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $26.40 | 2025 | |
| Progenics Pharmaceuticals, INC. | $21.38 | 2025 | |
| Legend Biotech USA INC. | $14.37 | 2025 | Carvykti |
| Pharmaand Gmbh | $10.18 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anouk Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.